Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Cure Ventures is a life sciences venture capital firm founded in 2021 and based in Boston, Massachusetts. The firm focuses on investing in the formation of new companies centered around groundbreaking curative technologies. Cure Ventures currently manages a portfolio of 12 companies.
Cure Ventures invests in de novo company formation primarily within the life sciences sector, targeting seed, Series A, and growth equity stages. Their investment strategy includes a seed funding model to de-risk scientific endeavors and genetic validation to enhance success probabilities. The firm collaborates closely with embedded operators to support entrepreneurs in daily decision-making.
Notable companies in Cure Ventures' portfolio include Aevum, which develops therapeutic molecules for Parkinson’s; Alessatherapeutics, focused on anti-androgen therapy for prostate diseases; Cenos, creating a blood-brain barrier shuttle platform; Clasp, innovating precision immuno-oncology; and Recuro, offering a virtual-first care delivery platform.
Submit your pitch through their form at curevc.com or email info@curevc.com with your deck.
Yes, Cure Ventures often leads funding rounds, particularly in the seed stage, to establish a strong foundation for new companies.
Cure Ventures is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their investment thesis.
Specific details about the fund size are not disclosed, but the firm actively manages a portfolio of 12 companies in the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.